What this category actually is, and why the panel decides it
The regulation, the one trial everybody cites, and the two sentences from that trial the marketing leaves out.
“Eye supplement” is a marketing category rather than a regulated one.
Nothing about the phrase tells you what is in the bottle. Walk the shelf and you will find
carotenoids, berry extracts, herbs named after the organ they are sold for, amino acids and
B vitamins, all under the same four or five words. The ingredients vary enormously. The
front-of-bottle vocabulary barely varies at all.
That matters because of how these products are regulated. A dietary supplement is not
approved by the FDA before it is sold. The seller may make a structure/function claim
— A structure/function claim may “describe the role of a nutrient or dietary ingredient intended to affect the normal structure or function of the human body, for example, ‘calcium builds strong bones.’” What the seller may not do is make a disease claim.
A disease claim says a product can “diagnose, treat, cure or prevent any disease”. Only drugs may legally make one. And the agency is explicit about what does not happen first:
These claims “are not pre-approved by FDA, but the manufacturer must have substantiation that the claim is truthful and not misleading and must submit a notification with the text of the claim to FDA no later than 30 days after marketing.” You never see the substantiation.
What AREDS2 actually found, and in whom
Two ingredients here do have a specific federal evidence base with published numbers
attached: lutein and zeaxanthin, tested by the National Eye Institute in the Age-Related Eye
Disease Studies. The AREDS2 formula was Vitamin C 500 mg, Vitamin E 400 IU, Copper (cupric oxide) 2 mg, Lutein 10 mg, Zeaxanthin 2 mg, Zinc 80 mg
— the numbers any eye supplement can be measured against, when it publishes enough of
its own to be measured.
Now the part the marketing almost never carries. AREDS2 ran in people who already
had intermediate or advanced age-related macular degeneration, and it was about
slowing progression in that group. NEI’s summary of both trials is two sentences:
“AREDS and AREDS2 supplements do not prevent AMD onset.” and
“None of the formulations decreased cataract risk.” A healthy-eyed buyer taking
an eye supplement because of a trial they half remember is taking it for a result that
trial did not produce in people like them. A third finding belongs on the front of every
bottle in the category and is on almost none: AREDS2 removed beta-carotene.
NEI: “Current and former smokers should take the AREDS2 formula and avoid the AREDS formula with beta-carotene, which increases lung cancer risk.” This label’s vitamin A is
beta-carotene.
Why reading the panel is the only defence a buyer has
Given all that, the Supplement Facts panel is not one source among several. It is the
only document in the transaction the seller is accountable for and that you can hold before
you swallow anything. The front of the bottle is an advertisement, seals included; the page
it is sold from is another one, written to different rules and not required to agree with
the label at all. The panel is the part with rules attached, and a panel that publishes its
amounts can be checked in a way marketing cannot. This one does it fifteen times, which lets
anybody see vitamin C at 200 mg against AREDS2’s 500 and zinc at 32 mg against 80.
Then it stops: lutein and zeaxanthin sit inside 240.5 mg shared eight ways
further. A blend total hides exactly the figure you came for.